- Latest available (Revised)
- Original (As made)
This is the original version (as it was originally made). This item of legislation is currently only available in its original format.
57.—(1) Subject to paragraphs (2) to (4), the Medicines (Products for Human Use) (Fees) Regulations 2010(1) (“the 2010 Regulations”) are revoked.
(2) The savings introduced by regulation 52(2), (3) and (4) of the 2010 Regulations shall continue to apply as if those paragraphs of that regulation had not been revoked.
(3) The 2010 Regulations shall continue to apply as if they had not been revoked—
(a)in relation to capital fees payable under the 2010 Regulations in respect of any application or inspection made before the date on which these Regulations come into force; and
(b)to any periodic fee payable under the 2010 Regulations in relation to a fee period ending before the date on which these Regulations come into force.
(4) The revocation of the 2010 Regulations shall not affect any proceedings under those Regulations for the recovery of any fees due as debts to the Crown and for the purposes of those proceedings, the 2010 Regulations shall continue to apply as if they had not been revoked.
Explanatory Memorandum sets out a brief statement of the purpose of a Statutory Instrument and provides information about its policy objective and policy implications. They aim to make the Statutory Instrument accessible to readers who are not legally qualified accompany any Statutory Instrument or Draft Statutory Instrument laid before Parliament from June 2004 onwards.
Impact Assessments generally accompany all UK Government interventions of a regulatory nature that affect the private sector, civil society organisations and public services. They apply regardless of whether the regulation originates from a domestic or international source and can accompany primary (Acts etc) and secondary legislation (SIs). An Impact Assessment allows those with an interest in the policy area to understand:
Click 'View More' or select 'More Resources' tab for additional information including: